Scilex Holding Company SCLX Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Royalty Payment Percentage On Net Sale by Business | ||||||
| Envelta | 6%+4.5pp | 1.5%0.0pp | 1.5%0.0pp | 1.5%0.0pp | 1.5%— | |
| Epoladerm | 6%+4.5pp | 1.5%0.0pp | 1.5%0.0pp | 1.5%0.0pp | 1.5%— | |
| Probudur | 6%+4.5pp | 1.5%0.0pp | 1.5%0.0pp | 1.5%0.0pp | 1.5%— | |
| Cost of Goods Sold by Product | ||||||
| Chargebacks | $1.34M— | —— | —— | —— | $885K-53.3% | |
| Estimated Sales Returns And Discount | $1.64M— | —— | —— | —— | $649K-71.6% | |
| Sales Rebates | $11.92M— | —— | —— | —— | $9.16M-52.6% | |
| Service Fees | $2.23M— | —— | —— | —— | $2M-52.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Scilex Holding Company break its business down?
- Scilex Holding Company (SCLX) reports royalty payment percentage on net sale by business across 3 parts — Envelta, Epoladerm and Probudur. Each is extracted from the segment footnotes and tracked over time.
- Where does Scilex Holding Company's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Scilex Holding Company's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
